Sharon Youngblood

“On January 10, 2024, the Company held an extraordinary general meeting of shareholders in lieu of an annual general meeting \(the “Shareholder Meeting”\) at which their shareholders approved: \(a\) an amendment to our Amended and Restated Memorandum and Articles of Association: \(i\) to change the date by which the Company must consummate a business combination to October 17, 2025 or such earlier date as is determined by the Board, in its sole discretion, to be in the best interests of the Company \(the “Extension Amendment”\); \(ii\) to remove the limitation that the company shall not redeem Class A ordinary shares included as part of the units sold in its initial public offering prior to the consummation of a business combination that would cause the Company’s net tangible assets to be less than $5,000,001 following such repurchases, \(the “Redemption Limitation Amendment”\); and \(iii\) to provide for the right of a holder of Class B ordinary shares, par value $0.0001 per share, to convert such shares into shares of the Company’s Class A ordinary shares on a one-for-one basis prior to initial business combination \(the “Conversion Amendment”\), and \(b\) the appointment of Richard Thompson and Sharon Youngblood as Class I directors to each serve on the Board for a three-year term expiring at the third succeeding annual general meeting after their appointment, or until their successors have been qualified and appointed.”